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Abstract
Rationale
Patients with chronic obstructive pulmonary disease (COPD) suffer from significantly more
cardiovascular comorbidity and mortality than would be anticipated from conventional risk
factors. The aim of this study was to determine whether COPD patients have a higher coro-
nary artery calcium score (CACS) and epicardial fat burden, compared to control subjects,
and their association with cardiovascular events.
Methods
From a registry of 1906 patients 81 patients with clinically diagnosed COPD were one-to-
one matched to 81 non-COPD control subjects with a smoking history, according to their
age, sex, and the number of classic cardiovascular risk factors (arterial hypertension, diabe-
tes mellitus, dyslipidemia, family history of premature coronary artery disease). CACS,
epicardial fat, and subsequent major adverse cardiovascular events (MACE) during follow-
up were compared between groups.
Results
Patients with COPD (Global Initiative for Chronic Obstructive Lung Disease-classification I:
5%, II: 23%, III: 16% and IV: 56%) showed no difference in CACS (median difference 68
Agatston Units [95% confidence interval -176.5 to 192.5], p=0.899) or epicardial fat volume
(mean difference -0.5 cm3 [95% confidence interval -20.9 to 21.9], p=0.961) compared with
controls. After a median follow-up of 42.6 months a higher incidence of MACE was observed
in COPD patients (RR=2.80, p=0.016) compared with controls. Cox proportional hazard re-
gression identified cardiac ischemias and CACS as independent predictors for MACE.
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Conclusion
COPD patients experienced a higher MACE incidence compared to controls despite no
baseline differences in coronary calcification and epicardial fat burden. Other mechanisms
such as undersupply of medication seem to account for an excess cardiovascular comor-
bidity in COPD patients.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limita-
tion. Globally, COPD is the fourth leading cause of death in industrialized countries.[1] The
clinical course of the disease is complicated by the development of systemic consequences and
comorbidities, particularly atherosclerosis and coronary artery disease (CAD), which is one of
the leading causes of death in COPD.[2] These comorbidities share common risk factors with
COPD and possibly similar pathogenic mechanisms, but may also be a consequence of COPD
itself and its pathophysiological effects on the vascular system.[3] The detection of new specific
cardiovascular risk markers (e.g. atherosclerotic plaques in preliminary stages) is therefore cru-
cial in this population in order to provide both powerful preventive and therapeutic measures.
Single-photon emission computed tomography (SPECT) is a robust diagnostic imaging tool
which can assess previously unknown myocardial scar tissue or ischemia as potential predic-
tors for future risk assessment.[4] Furthermore, the coronary artery calcium score (CACS) and
the epicardial fat volume can be derived from the non-contrast computed tomography used for
attenuation correction. The CACS is a well-accepted method for the detection of subclinical
CAD at a very early disease-onset and acts as a strong predictor of future major adverse cardio-
vascular events (MACE).[5] Epicardial fat, on the other hand, is a relatively novel marker
which reflects local adipose tissue within the visceral layer of the pericardium where it embeds
the coronary arteries. Due to this proximity to the epicardial coronary arteries, it is thought
that these fat depots may contribute to the development of coronary atherosclerosis through
paracrine effects of inflammatory cytokines.[6] Furthermore clinical studies have suggested
that epicardial fat is associated with vascular calcification[7] and may help to improve predic-
tion of MACE[8] in asymptomatic patients. Therefore, CACS and epicardial fat may contribute
additive prognostic information on the cardiovascular burden in COPD patients.
There are few and conflicting data on the relationship between COPD and subclinical CAD
and some of the published studies are limited by inadequate matching of classic cardiovascular
risk factors between COPD patients and control subjects.[9–12] The evidence to date warrants
studies with follow-up and carefully considering the higher prevalence of hypertension, diabe-
tes mellitus, and dyslipidemia among COPD patients compared with the general population.
[13,14] Therefore, we conducted a one-to-one matched cohort study to evaluate whether
COPD patients present a higher degree of coronary atherosclerosis and epicardial fat burden
and to investigate the possible excess risk of COPD for MACE independent of established car-
diovascular risk factors.
Methods
Study design
In this one-to-one matched cohort study COPD patients (at the University Hospital Zurich
between 01.01.2007 and 31.07.2013) were screened for the following inclusion criteria: (1.)
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coronary artery calcium score (CACS) data available; (2.) history of smoking (smoker or ex-
smoker with a smoking history of10 pack-years [PY]); (3.) objectively confirmed COPD.
COPD was staged according to Global Initiative for Chronic Obstructive Lung Disease
[GOLD]-guidelines 2007[15] and spirometry results are expressed in percentage of predicted
values according to the European reference equations[16]. Subjects were excluded according to
the presence of one of the following exclusion criteria: (1.) coronary symptoms (Canadian Car-
diovascular Society Angina Grading Scale1) at the time of the SPECT investigation; (2.)
known congenital or structural heart disease; (3.) previous heart transplantation. Controls
were selected according to the same in- and exclusion criteria, however, without COPD. Classic
cardiovascular risk factors were: treatment for (1.) hypertension, (2.) hypercholesterolemia,
and (3.) diabetes mellitus, (4.) family history of premature MACE (first-degree family member:
men<55, women<65 years of age), and (5.) obesity (body mass index [BMI]>30kg/m2).
MACE were defined as documented death due to a cardiovascular event, non-fatal infarction
(including stroke), documented transient ischemic attack, catheter-based target lesion revascu-
larization, unstable angina pectoris requiring hospitalization, and coronary artery bypass graft.
Each COPD subject was 1-to-1 matched with one non-COPD subject for: (1.) sex (exact),
(2.) number of classic cardiovascular risk factors (exact), and (3.) age. Age (normally distribut-
ed) was matched via nearest neighbour matching with a maximum allowable difference of one
standard deviation between two participants. Matching was performed without replacement
and optimal in order to minimize the total within pair differences. COPD subjects for whom
no control case was found within the maximum absolute distance (n = 25) were left unmatched
and excluded from analysis. Hence, only 81 (76%) of the COPD subjects were included in the
analysis. Balance assessment in measured baseline covariates was additionally performed with
the standardized difference, which is the difference in means in units of the pooled standard
deviation.[17]
This study complies with the Declaration of Helsinki of the World Medical Association,
ICH-GCP-Guidelines. The study protocol was approved by the Local Ethics Committee of the
Canton of Zurich (KEK-ZH-Nr. 2013–0615) and registered with the study ID NCT02162095
(clinicaltrials.gov). Patients were included in the study if they had signed informed consent au-
thorizing their records to be included in our cardiac imaging research registry. All patients un-
derwent clinically indicated cardiac SPECT. Informed consent for the longitudinal part of the
study (follow-up) was obtained separately from all patients or relatives in case of a deceased pa-
tient which was recorded by an investigator on the case report form. The ethics committee ap-
proved this procedure due to the low risk category this study entails.
SPECT
All patients underwent a one-day pharmacological stress/rest SPECTMyocardial Perfusion
Imaging protocol according to the guidelines of the European Association of Nuclear Medi-
cine.[18] All cardiac SPECT studies were ECG-triggered. Data acquisition was performed with
a dual-head detector hybrid SPECT/CT camera (Millenium VG and Hawkeye; GE Healthcare)
or an ultrafast CZT camera (Discovery 530 NMc, GE Healthcare). Images were viewed on a
dedicated workstation (Xeleris; GE Healthcare) and analysed by experts blinded to the group-
ing of patients.
The CACS was calculated in clinical routine using a commercially available semi-automatic
software (SmartScore, GE Healthcare, Milwaukee, USA) according to the Agatston scoring
method and expressed in Agatston Units (AU).[6] The area of coronary artery calcium was de-
fined as automatically detected pixels with a noncontrast computed tomography density of
130 Hounsfield Units (HU) within manually selected lesions. The total CACS was computed,
Cardiovascular Risk in COPD
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compromising the sum of the lesions in the left anterior descending artery, left circumflex ar-
tery, and right coronary artery. Epicardial fat and thoracic fat were calculated by two indepen-
dent investigators (TG, MP) by a dedicated software (QFAT, Cedars-Sinai Medical Center, Los
Angeles, CA, USA) which has been validated and previously described.[8,19,20] Conventional
thresholds between -190 HU to -30 Hounsfield units (HU) were used to define three-dimen-
sional fat voxels on a noncontrast computed tomography and findings are reported in cm3.
Epicardial and thoracic fat were cranially confined by the first CT-slice displaying the bifurca-
tion of the pulmonary trunk and caudally by the most inferior CT-slice of the myocardium.
Epicardial fat was defined as detected fat-voxels within the visceral pericardium including all
fat surrounding the coronary arteries while thoracic fat was defined as detected fat-voxels with-
in the thoracic cavity limited by the posterior limit of the heart.[20] Therefore thoracic fat com-
prises epicardial fat. For each slice, pericardial contours were traced by manually placing a few
control points (8–12) on the visceral pericardium, and epicardial fat, defined as fat voxels
bounded by the visceral pericardium, was measured.[20] The thoracic fat was calculated auto-
matically and corrected manually if necessary.[20]
Follow-up
Follow-up was conducted either via personal contact, or with the help of the Swiss Federal De-
partment of Justice and Police (Swiss register “Infostar”). Information was cross-checked and
validated from internal and requested external medical charts with formal approval of the pa-
tient. All medical charts were obtained and MACE were critically reviewed by two investigators
(TG, CS) unaware of the participants allocation. All deaths were categorized into cardiac or
non-cardiac. The freedom fromMACE time of a patient started at the time of SPECT imaging
and ended at death/MACE, or at the last follow-up day. This method did not account for recur-
ring MACE in one subject. Therefore, overall MACE rate was expressed as MACE/follow-up
year.
Statistical analysis
Continuous data are expressed as mean (±SD), or in the case of non-normal distribution by
their median (quartiles). Paired tests (shared frailty) were used for matched pairs in this study.
Ln(CACS+1) was used to investigate CACS-relationships with other variables. Continuous and
categorical baseline characteristics of COPD and non-COPD subjects were compared using
Wilcoxon and Pearson chi-square tests respectively. Spearman correlation analysis was used to
investigate correlations with the CACS. Cumulative freedom fromMACE at follow-up was
analysed by means of the Kaplan—Meier method and compared between groups using the log-
rank test. Univariable and multivariable (stepwise backward selection manner) Cox propor-
tional hazard regression models were used to identify possible predictors of MACE. Further-
more, age, sex, and number of cardiovascular risk factors were also adjusted for multivariable
analysis. Data analysis was conducted using IBM SPSS Statistics v. 22.0 software (IBM Corpo-
ration, Armonk, NY). A two-sided p value of<0.05 was considered to indicate
statistical significance.
Results
Patient characteristics
Of the 1906 patients screened, 81 matched pairs entered the data analysis. Fig 1 summarizes
the patient flow. The within-pair standardized age difference was 0.1%. Baseline characteristics
are shown in Table 1.
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The study population had a mean age of 64 years and was predominantly male (78%). All
COPD GOLD stages were represented, but most of the COPD patients were in GOLD stage IV
(I: 5%, II: 23%, III: 16% and IV: 56%). Apart from the anticipated differences in the lung func-
tion test and consumed PY, the two cohorts differed in BMI (but not obesity) and number of
prescribed ß-blockers. Follow-up was successful in 154 (95%) patients, five patients were lost
in the COPD group and three patients in the control group.
SPECT
CACS did not differ significantly between the COPD group and the control group (245 [38,
1404] vs. 313 [47, 1061] AU, p = 0.893) nor in any GOLD stage compared to the controls adjust-
ed for age, sex, number of cardiovascular risk factors, and smoking status (data not shown). Fat-
quantification was successful in all but one patient (insufficient image quality). There was no
significant mean (SD) group difference in epicardial and thoracic fat between the COPD group
and the control group (132.6±69.2 vs. 132.3±90.2 cm3, p = 0.961 and 277±139.5 vs. 283.0±149.8
cm3, p = 0.931 respectively). Epicardial and thoracic fat correlated highly (r = 0.91, p<0.001)
whereas correlation of epicardial and thoracic fat with CACS (r = 0.31, p<0.001 and r = 0.35,
p<0.001 respectively) and BMI (r = 0.52, p<0.001 and r = 0.61, p<0.001) was moderate. CACS
and epicardial fat correlated with the number of cardiovascular risk factors and detected scars in
the SPECT (all p<0.001).
Follow-up
During 410 person-years follow-up a total of 28 MACE (19 COPD vs. 9 controls, p = 0.030)
and 48 deaths (26 COPD vs. 22 controls, p = 0.423) occurred. Median follow-up was 42.6
(21.1, 60.0) months and did not differ between groups (p = 0.543). Kaplan-Meier analysis (Fig
2) indicated that patients with COPD suffered from significantly more MACE (log-rank
Fig 1. Patient flow chart.
doi:10.1371/journal.pone.0126613.g001
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Table 1. Patient characteristics.
COPD group Control group p value
N 81 81 -
Age, years (±SD) 64.3 (±10.3) 64.3 (±9.1) -
Sex (m / f) 63/18 63/18 -
Traditional cardiovascular risk factors, N (±SD) 1.4 (±1.1) 1.4 (±1.1) -
Arterial hypertension, N (%) 51 (63) 50 (62) 0.782
Diabetes mellitus, N (%) 17 (21) 17 (21) -
Dyslipidemia, N (%) 34 (42) 29 (36) 0.166
Family history for early cardiovascular events, N (%) 8 (10) 14 (17) 0.157
Obesity, N (%) 12 (15) 12 (15) -
Body mass index, kg/m2 (±SD) 24.2 (±5.8) 26.7 (±4.9) <0.001
CACS, AU (quartiles) 245 (38, 1404) 313 (47, 1061) 0.893
Epicardial fat, cm3 (±SD) 132.6 (±69.2) 132.3 (±90.2) 0.961
Thoracic fat, cm3 (±SD) 277 (±139.5) 283.0 (±149.8) 0.931
Left ventricular ejection fraction, % (±SD) 62.9 (±9.8) 63.47 (±10.7) 0.770
Scars in SPECT, N (%) 7 (9) 12 (15) 0.251
Ischemia in SPECT, N (%) 11 (14) 8 (10) 0.467
Current smoker, N (%) 25 (31) 36 (44) 0.071
CRP, ng/la (quartiles) 4 (1.1, 7.2) 4.1 (2, 10) 0.545
PY, N (±SD) 50.7 (±22.2) 31.7 (±20.0) <0.001
FEV1 (% pred.)
b (quartiles) 28 (22, 66) 87 (68.8, 97.3) <0.001
FVC (% pred.)b (±SD) 71 (±19) 99 (±15) <0.001
FEV1/FVC, %
b (quartiles) 37 (28, 58) 76 (71.8, 81) <0.001
GOLD Stage
I, N (%) 4 (5)
II, N (%) 19 (23)
III, N (%) 13 (16)
IV, N (%) 45 (56)
Medication
ß-blocker, N (%) 20 (25) 40 (49) 0.001
Antihypertensive agents without ß-blocker, N (%) 51 (63) 59 (73) 0.059
Lipid-lowering agents, N (%) 28 (35) 29 (36) 0.617
Platelet aggregation inhibitor, N (%) 34 (42) 34 (42) -
Previous MACE, N (%) 19 (23) 19 (23) -
Stroke, N (%) 4 (5) 6 (7) 0.527
Myocardial infarction, N (%) 3 (4) 8 (10) 0.132
Coronary artery bypass grafting, N (%) 1 (1) 0 (0) 0.317
Percutaneous coronary intervention, N (%) 9 (11) 7 (9) 0.617
AU = Agatston units; CACS = coronary artery calcium score; COPD = chronic obstructive lung disease; CRP = C-reactive protein; FEV1 = forced
expiration in one second; FVC = forced vital capacity; GOLD = Global Initiative for Obstructive Lung Disease; MACE = major adverse cardiovascular
event; PY = pack years of smoking; SPECT = single-photon emission computerized tomography
a Data available from 71 (87.7%) COPD subjects and 67 (82.7%) control subjects
b Data available from 79 (97.5%) COPD subjects and 49 (60.5%) control subjects
doi:10.1371/journal.pone.0126613.t001
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p = 0.016, RR = 2.80), especially myocardial infarction. The overall rate of death and myocardial
infarction did not differ significantly between the COPD and control group (log-rank p = 0.115).
MACE/follow-up year was 10.3% in the COPD group and 3.9% in the control group respectively
(p = 0.015). CACS was significantly higher in patients with COPD who experienced MACE or
death within the follow-up period compared to those who survived free of MACE and death
(MACE: 1342 AU [387, 2414] vs. 204 [49, 1116] AU, p<0.001 / Death: 771 [46, 1659], vs. 218
AU [55, 1144], p = 0.011). For a summary on follow-up statistics see Table 2.
Univariable logistic regression analysis demonstrated that COPD, CACS, FEV1 (% pred.),
PY, ischemia in SPECT imaging, and previous CAD were risk factors for MACE (Table 3). In
the multivariable Cox-regression analysis adjusted for age, sex, number of cardiovascular risk
factors, BMI, ß-blockers, PY, and COPD, both ischemia in SPECT imaging and CACS were
predictors of MACE (Table 4).
Discussion
This is the first one-to-one matched cohort study investigating whether COPD might be an in-
dependent risk factor for coronary atherosclerosis, epicardial fat burden and MACE. The main
finding of this study is that although CACS and epicardial fat were not different in COPD pa-
tients compared to matched control subjects, MACE do occur more frequently in COPD and
the incidence of MACE is independently associated with the degree of CACS. The underlying
mechanisms between COPD and CAD are not fully understood. Mechanisms that have been
proposed to explain the observed association between COPD and cardiovascular disease in-
clude systemic inflammation, hypoxia, oxidative stress, sympathetic activation, connective
Fig 2. Kaplan-Meier curves for the study population.
doi:10.1371/journal.pone.0126613.g002
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tissue alteration, increased platelet activation, impaired endothelial function and impaired
physical activity.[3,21] COPD and CAD frequently occur concurrently, and the rate of non-
fatal and fatal cardiovascular events is consistently increased in COPD patients.[22,23] The re-
lationship between COPD and cardiovascular disease, particularly CAD, has been studied in
previous observational cohort and case-control studies, and the degree of airflow limitation has
been shown to be an independent predictor of cardiovascular events in the general population
Table 2. Follow-up statistics.
COPD group Control group p value
N 76 78 0.924
Lost to follow-up, N (%) 5 (7) 3 (4) 0.445
Median follow-up time, months (quartiles) 39.6 (20.8, 58.6) 46.0 (15.1, 60.0) 0.172
Patients with MACE, N (%) 19 (25) 9 (12) 0.030
MACE, N (%) 24 (32) 13 (17) 0.031
Annual MACE rate, % 10.3 3.9 0.015
Myocardial infarction, N (%) 5 (7) 0 (0) 0.022
Angina pectoris, N (%) 0 (0) 1 (1) 0.311
Percutaneous coronary intervention, N (%) 11 (14) 9 (12) 0.589
Stroke, N (%) 1 (1) 2 (3) 0.576
Transient ischemic attack, N (%) 3 (4) 0 (0) 0.077
Coronary artery bypass grafting, N (%) 2 (3) 1 (1) 0.538
Cardiac death, N (%) 2 (3) 0 (0) 0.153
Non-cardiac death, N (%) 26 (34) 22 (28) 0.423
COPD = chronic obstructive lung disease; MACE = major adverse cardiovascular event
doi:10.1371/journal.pone.0126613.t002
Table 3. Predictors of MACE in unadjusted analysis in a one-to-onematched cohort for age, sex and number of cardiovascular risk factors.
Predictors Univariable B Univariable 95% CI p value
Age, (per 10 years) 1.00 1.00 / 1.00 0.744
Sex, male 1.62 0.65 / 7.18 0.211
Traditional cardiovascular risk factors, N 1.27 0.90 / 1.75 0.183
BMI, kg/m2 0.98 0.85 / 1.03 0.197
CACS, per 100 AU 1 1.00 / 1.00 0.002
Epicardial fat, cm3 1 0.99 / 1.00 0.973
Thoracic fat, cm3 1 0.99 / 1.00 0.371
GOLD classiﬁcation 1.27 1.03 / 1.57 0.031
PY, N 1.01 1.00 / 1.03 0.033
Left ventricular ejection fraction, % 0.99 0.96 / 1.02 0.496
CRP, ng/la 0.99 0.97 / 1.02 0.770
β-blocker 0.68 0.30 / 1.50 0.340
Initial ischemia in SPECT 3.32 1.45 / 8.22 0.005
Initial scar in SPECT 2.01 0.79 / 5.54 0.137
Previous coronary artery disease 2.35 1.15 / 5.37 0.020
AU = Agatston units; CACS = coronary artery calcium score; COPD = chronic obstructive lung disease; CRP = C-reactive protein; FEV1 = forced
expiration in one second; FVC = forced vital capacity; GOLD = global initiative for chronic obstructive lung disease; MACE = major adverse cardiovascular
event; PY = pack years of smoking; SPECT = single-photon emission computerized tomography
a Data available from 71 (87.7%) COPD subjects and 67 (82.7%) control subjects
doi:10.1371/journal.pone.0126613.t003
Cardiovascular Risk in COPD
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implying a causal relationship between airflow limitation and cardiovascular disease.[24]
There is also evidence that CACS correlates with overall mortality in COPD patients.[25] Our
data from this COPD cohort confirms the validity of the CACS in predicting MACE in this
population whereas the association with mortality was non-significant. To date four studies in-
vestigating CACS as a surrogate for CAD in patients with COPD have been published which
yielded inconsistent results.[9–12] One matched controlled study[12] found no difference
whereas three studies using regression analysis found higher CACS in COPD patients when
compared to non-COPD patients.[9–11] An explanation for some of the conflicting data could
be the different study designs and/or deficiency of previous studies in controlling for potential
cardiovascular (and atherosclerotic) risk factors which are highly prevalent in this population.
[13,14] The correlation of the CACS with myocardial scars and other CAD risk factors in our
study underpins the importance of matching. In respect of the study population, our study
mainly included severe COPD cases, whereas the above mentioned studies mainly refer to
COPD cohorts with mild or moderate disease. Furthermore, our findings are supported by the
results of the large population based Multi-Ethnic Study of Atherosclerosis (MESA) study,
which investigated 3642 participants aged 45–84 years without clinical cardiovascular disease
and found no association between CACS and lung function or extent of lung emphysema.[26]
The Framingham heart study found an association of epicardial fat with coronary calcium
and preliminary findings suggest epicardial fat may help to improve prediction of MACE.[7]
While our results support the first association, epicardial fat was not associated with MACE in
our study. Our data, however, show that epicardial fat is significantly associated with relevant
CAD markers such as CACS, the number of cardiovascular risk factors, BMI, myocardial scars
in SPECT, consumed PY, and male gender. To date, there is only one published study which
investigated epicardial fat specifically in COPD patients.[12] In that study Zagaceta et al.[12]
compared 171 COPD patients (with mostly mild disease) to 70 patients controlled for age,
smoking history and BMI but nor for other classic cardiovascular risk factors and found that
COPD patients had a higher epicardial fat volume (p = 0.02) than controls. Our study could
not reproduce these findings in a COPD population with mostly severe COPD patients, as no
association of COPD with epicardial or thoracic fat volume was found.
Perhaps the most intriguing finding of our study is the higher MACE incidence during fol-
low-up in patients with COPD compared to the control group despite absent baseline differ-
ences in classic cardiovascular risk factors. This high MACE incidence is in agreement with
results from a cohort study where a more than two-fold increase in the rate of hospitalizations
due to cardiovascular events was found in patients with COPD compared with matched con-
trol subjects without COPD.[27] Underlying causes explaining the higher risk of cardiovascular
events in COPD patients may include substandard medical care in regards to evidence-based
Table 4. Predictors of MACE in multivariable analysis adjusted for age, male sex, and number of cardiovascular risk factors.
Predictors Multivariable B Multivariable 95% CI p value
CACS, per 100 AU 1.01 1.00 / 1.02 0.004
GOLD classiﬁcation 1.13 0.85 / 1.50 0.389
Initial ischemia in SPECT 3.22 1.21 / 7.79 0.018
BMI, kg/m2 0.97 0.90 / 1.04 0.426
Pack years of smoking, yrs 1.02 0.99 / 1.03 0.073
Beta-blockers 0.75 0.28 / 1.98 0.564
AU = Agatston units; BMI = body mass index; CACS = coronary artery calcium score; GOLD = Global Initiative for Chronic Obstructive Lung Disease;
MACE = major adverse cardiovascular event; SPECT = single-photon emission computerized tomography
doi:10.1371/journal.pone.0126613.t004
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medications, such as blood pressure medications. In the present study, patients with COPD
were significantly less likely to receive antihypertensive agents, compared with the control
group which is in line with further large population studies.[28,29] Possibly this is due to the
fear, that especially non-selective ß-blockers and their assumed pulmonary side-effect in
COPD patients may impair pulmonary function and increase the risk of disease exacerbation.
[30] Thus it may be that substandard medical treatment in COPD patients is a contributor to
the observed higher rate of MACE in such patients as several studies have demonstrated im-
proved health outcomes are associated with ß-blockers in patients with COPD.[31]
A limitation of this study relies in the fact that CT-derived CACS is only a quantitative mea-
sure for overall calcium burden and therefore cannot assess morphological aspects of athero-
sclerotic lesions. A controlled coronary angiography study reported that COPD patients have
worse morphological properties of atherosclerotic lesions which might explain the relatively
high myocardial infarction-rates among COPD patients in our study.[32] The vulnerability of
arteriosclerotic plaques is also thought to be influenced by the autonomic nervous system
which has been shown to be altered in COPD patients.[33] Mechanisms like sympathetic over-
activity and subsequent plaque rupture (due to hypoxia, inflammation, oxidative stress, physi-
cal inactivity and intrathoracic pressure changes)[33] but also impaired endothelial
dysfunction[3] and subsequent vasospasm[34] have been suggested to contribute to the cardio-
vascular excess comorbidity in COPD patients. There is also epidemiological support for the
concept that acute respiratory tract infections (which COPD patients are prone to) can precipi-
tate MACE.[35]
Lastly, the possibility of lower levels of physical activity must be taken into account, as this
is a frequently observed problem in patients with COPD.[36] The significance of exercise is
somewhat supported by the findings of the recent NAVIGATOR trial which suggests that rela-
tively small differences in daily physical activity (i.e. 2000 steps) may account for a higher risk
of cardiovascular events in high risk populations.[37] However, in the current study we did not
assess physical activity levels and thus this needs to be explored in future studies.
It is important to note that the study design of the current study does not allow establishing
a causal relationship between COPD and cardiovascular excess comorbidity. However, it is ex-
tremely difficult to perform a randomized controlled trial to explore the cardiovascular effects
of COPD as except for surgical treatment of emphysema (i.e. lung volume reduction surgery)
there is no therapy which has a profound effect on disease severity. The relatively small sample
size mainly due to restrictive 1-to-1 matching and limited amount of COPD patients undergo-
ing SPECT also remains a limitation of this study.
In conclusion, there is an excess cardiovascular comorbidity in COPD patients which can-
not be explained by coronary calcification or epicardial fat burden and thus further well de-
signed studies with a focus on medication and comorbidities are needed to investigate the
mechanisms underpinning the association between COPD and cardiovascular disease.
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